Week In Review
View More From This Discussion
Episode 1 - CRPC: Recent Advances and Paradigm Shifts in Treatment
During the opening segment of this panel discussion about recent advances and pharmacoeconomic considerations in the clinical management of Castration-Resistant Prostate Cancer (CRPC), leading experts briefly discuss the clinical and economic burden of CRPC, and explain how a paradigm shift in treatment is improving the disease's outlook.
Episode 2 - Immunotherapy in CRPC
David Crawford, MD, and David Quinn, MD, discuss the capabilities of new immunotherapy and hormonal agents for the treatment of castration-resistant prostate cancer, as demonstrated by the results of several key clinical trials.
Episode 3 - Radium-223 for the Treatment of CRPC
In addition to cytotoxic chemotherapy, immunotherapy, and oral agents that target the androgen pathway, David Crawford, MD, discusses radium-223 as a therapeutic option for the treatment of castration-resistant prostate cancer.
Episode 4 - Treatment Guidelines and Economic Considerations
During this segment, Raoul S. Concepcion, MD, discusses the rapid development of expensive agents for castration-resistant prostate cancer and explains how treatment costs create a challenge to clinicians and payers. Michael Kolodziej, MD, responds by explaining what variables payers consider when making decisions about treatment coverage.
Episode 5 - Pharmacoeconomic Considerations
During this segment, the panelists continue discussing the rapid development of specialty drugs for the treatment of castration-resistant prostate cancer and determine the importance for a drug sequencing plan.
Episode 6 - Treatment Response Rates in Step Therapy
During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss ways to address poor treatment response among patients with castration-resistant prostate cancer who require step therapy.
Episode 7 - Treatment Coverage in Castration-Resistant Prostate Cancer
During this segment, the panelists explore issues faced by managed care during treatment coverage decisions in castration-resistant prostate cancer (CRPC).
Episode 8 - Impact of Payment Reform on Prostate Cancer Treatment
Dr Dunn invites fellow panelists to discuss the role of payment reform in managing prostate cancer. He suggests that better-aligned incentives will allow payers and providers to make better decisions about medications or other treatment options.
Episode 9 - Benefit Design and Making Treatment Affordable
Dr Dunn introduces the discussion of benefit design, suggesting that managed care providers may be unprepared to administer specialty drugs.
Episode 10 - End-of-Life Care in CRPC
During this segment, the panelists consider the variables and programs that assist providers when they counsel and care for patients during end-of-life scenarios.
Episode 11 - Personalized Medicine in CRPC
During this segment, the panelists review the use of personalized medicine in castration-resistant prostate cancer.
Episode 12 - Specialty Pharmacy's Role in CRPC
During this segment, the panelists discuss specialty pharmacy's role in urology and explore how this shift in care creates hurdles for providers and their patients.
Episode 13 - Final Insights
During the conclusion of this panel discussion, the panelists provide their final insights about managed care's role in castration-resistant prostate cancer.
Improving HCV Cure Rates in HIV-Coinfected Patients—A Real-World Perspective
Sofosbuvir Initial Therapy Abandonment and Manufacturer Coupons in a Commercially Insured Population
Real-World Outcomes of Ledipasvir/Sofosbuvir in Treatment-Naïve Patients With Hepatitis C
More on AJMC.COM
No Result Found
ACO COALITION >
CONTINUING EDUCATION >
Heart Failure Compendium
About Us >
Terms & Conditions
MJH Associates >
Specialty Pharmacy Times
Copyright AJMC 2006-2016
All Rights Reserved.